What You Should KnowTel Aviv-based AI clinical simulation platform QuantHealth closed a $45 million Series B financing round led by Qumra Capital. Proceeds will advance next-generation AI models, deepen scientific validation, expand therapeutic coverage beyond 40 indications, and expand product offerings across the clinical and commercial lifecycles. Bypassing 90% Drug Failure Rates: QuantHealth Scales Simulation-First Development with Qumra and SanofiQuantHealth has raised $45M in Series B financing to scale its simulation-first clinical trial platform, targeting the biopharmaceutical industry’s persistent 90% drug failure rate. The company’s predictive tools are already embedded in clinical development workflows at 12 of the top 20 global pharmaceutical companies. “Today, clinical development decisions are still largely made through real-world iteration—running trials, waiting for results, and adjusting at significant cost and risk.